The “Fondation d’Entreprise Bristol Myers Squibb pour la Recherche en Immuno-Oncologie” aims to encourage innovation and to support French research in Immuno-Oncology and Pediatric Oncology. One of the challenges is to facilitate the work of French researchers in the field of Immuno-Oncology, on therapeutic approaches that particularly offer hope for patients. The projects funded each year are selected by the Board of Directors of the Fondation Bristol Myers Squibb (BMS), after their evaluation and classification by the Foundation's Scientific Committee.
In the Basic Research category, two projects, led by Luca Simula (Cancer and Immune Response team), in collaboration with Clotilde Alves-Guerra, and by Julie Helft (Phagocytes and Cancer Immunology team) are among the 7 winners of the 2024 call for projects.